Theratechnologies Current Ratio 2011-2021 | THTX

Theratechnologies current ratio from 2011 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Theratechnologies Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-08-31 $0.10B $0.04B 2.22
2021-05-31 $0.10B $0.04B 2.41
2021-02-28 $0.10B $0.04B 2.59
2020-11-30 $0.07B $0.04B 1.55
2020-08-31 $0.06B $0.03B 1.90
2020-05-31 $0.07B $0.04B 1.92
2020-02-29 $0.07B $0.03B 2.18
2019-11-30 $0.08B $0.04B 2.05
2019-08-31 $0.07B $0.03B 2.51
2019-05-31 $0.07B $0.03B 2.69
2019-02-28 $0.07B $0.03B 2.46
2018-11-30 $0.07B $0.03B 2.74
2018-08-31 $0.07B $0.02B 2.89
2018-05-31 $0.03B $0.02B 1.36
2018-02-28 $0.03B $0.02B 1.56
2017-11-30 $0.03B $0.02B 1.56
2017-08-31 $0.03B $0.02B 1.76
2017-05-31 $0.03B $0.02B 1.84
2017-02-28 $0.03B $0.01B 2.64
2016-11-30 $0.02B $0.01B 1.84
2016-08-31 $0.02B $0.01B 1.70
2016-05-31 $0.02B $0.01B 1.55
2016-02-29 $0.02B $0.01B 1.79
2015-11-30 $0.03B $0.01B 2.04
2015-08-31 $0.03B $0.02B 1.86
2015-05-31 $0.02B $0.02B 1.25
2015-02-28 $0.02B $0.01B 1.57
2014-11-30 $0.02B $0.01B 1.54
2014-08-31 $0.01B $0.01B 1.65
2014-05-31 $0.01B $0.01B 1.89
2014-02-28 $0.01B $0.01B 2.29
2013-11-30 $0.01B $0.01B 2.81
2013-08-31 $0.01B $0.00B 3.21
2013-05-31 $0.02B $0.01B 3.53
2013-02-28 $0.02B $0.01B 2.44
2012-11-30 $0.02B $0.01B 2.67
2012-08-31 $0.02B $0.01B 2.03
2012-05-31 $0.02B $0.01B 2.07
2012-02-29 $0.02B $0.01B 2.08
2011-11-30 $0.02B $0.01B 1.61
2011-08-31 $0.02B $0.01B 1.43
2011-05-31 $0.00B 0.00
2011-02-28 $0.00B 0.00
2010-11-30 $0.00B 0.00
2010-08-31 $0.00B 0.00
2010-05-31 $0.00B 0.00
2010-02-28 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.333B $0.066B
Theratechnologies, Inc. is a pharmaceutical company focusing on the development of therapeutic peptide products with an emphasis on growth-hormone releasing factor peptides. It's main product EGRIFTA is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy which is marketed primarily in the United States, Latin America, Africa, the Middle East, Europe, Russia, South Korea, Taiwan, and Thailand. Theratechnologies, Inc. is headquartered in Montreal, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86